| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7341744 | NAPO PHARMS INC | Method of treating secretory diarrhea with enteric formulations of proanthocyanidin polymer |
Jun, 2022
(1 year, 3 months ago) | |
| US9585868 | NAPO PHARMS INC | Methods and compositions for treating HIV-associated diarrhea |
Oct, 2031
(8 years from now) | |
| US8962680 | NAPO PHARMS INC | Methods and compositions for treating HIV-associated diarrhea |
Oct, 2031
(8 years from now) | |
Mytesi is owned by Napo Pharms Inc.
Mytesi contains Crofelemer.
Mytesi has a total of 3 drug patents out of which 1 drug patent has expired.
Expired drug patents of Mytesi are:
- US7341744
Mytesi was authorised for market use on 31 December, 2012.
Mytesi is available in tablet, delayed release;oral dosage forms.
Mytesi can be used as symptomatic relief of non-infectious diarrhea.
The generics of Mytesi are possible to be released after 31 October, 2031.
Drugs and Companies using CROFELEMER ingredient
Market Authorisation Date: 31 December, 2012
Treatment: Symptomatic relief of non-infectious diarrhea
Dosage: TABLET, DELAYED RELEASE;ORAL
MYTESI family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic